MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1494)	5/18/2004 4:33:00 PM
From: Icebrg	Read Replies (1) of 1826

MGI Pharma "market outperform" Tuesday, May 18, 2004 1:07:25 PM ET JMP Securities NEW YORK, May 18 (New Ratings) - Analyst Howard Liang of JMP Securities maintains his "market outperform" rating on MGI Pharma Inc (MOGN.NAS). The target price is set to $75. In a research note published this morning, the analyst mentions that the April sales of the company's Aloxi drug are likely to have exceeded expectations. MGI Pharma's Aloxi drug, which is in the early stage of market penetration, is expected to offer substantial earnings growth opportunities in the forthcoming quarters, the analysts say. The company is likely to pursue acquisitions in the near term to boost its product portfolio, JMP Securities adds.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next